Perrigo Company plc or Amicus Therapeutics, Inc.: Who Manages SG&A Costs Better?

SG&A Cost Management: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Perrigo Company plc and Amicus Therapeutics, Inc. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Perrigo's SG&A expenses have consistently been higher, peaking at approximately $1.27 billion in 2023. In contrast, Amicus Therapeutics started with a modest $20 million in 2014, growing to $275 million by 2023. Despite this growth, Amicus's expenses remain a fraction of Perrigo's, highlighting their leaner operational model. This disparity underscores the different scales and strategies of these companies. While Perrigo's expenses are nearly five times higher, Amicus's rapid growth in SG&A costs suggests an aggressive expansion strategy. Investors and analysts should consider these trends when evaluating the financial health and strategic direction of these companies.